Treatment

Eytan M. Stein, MD

High Rate of IDH1 Mutation Clearance and MRD Negativity in Patients with IDH1 Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Published on May 27, 2020 in Treatment

Alexander Perl, MD

How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent?

Published on May 6, 2020 in Treatment

Alexander Perl, MD

How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?

Published on May 6, 2020 in Treatment

Naval Daver, MD

Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Published on April 22, 2020 in Treatment

Eytan M. Stein, MD

How to utilize and sequence new drugs in the treatment of AML

Published on April 10, 2020 in Treatment

Daniel A. Pollyea, MD

Are there certain agents which could be selected for treatment which may lessen immunosuppression?

Published on April 8, 2020 in Treatment

Daniel A. Pollyea, MD

In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients?

Published on April 8, 2020 in Treatment

Daniel A. Pollyea, MD

What education instruction are you providing to your patients with AML who are already immunocompromised and are you continuing treatment as planned?

Published on April 8, 2020 in Treatment

Daniel A. Pollyea, MD

How are you managing care delivery during the COVID-19 pandemic?

Published on April 8, 2020 in Treatment

Alexander Perl, MD

What are the advantages and disadvantages of the different FLT3 inhibitors?

Published on April 1, 2020 in Treatment